Semax vs Cerebrolysin: what the research actually compares

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed from a fragment of adrenocorticotropic hormone (ACTH), specifically ACTH(4-10), and is studied as a peptide-based nootropic and neuroprotective agent. Cerebrolysin is a multimodal neuropeptide preparation derived from porcine brain tissue, containing low-molecular-weight peptides and free amino acids, and is studied as a neurotrophic and neuroprotective agent in neurological injury and neurodegeneration. The two compounds are frequently grouped together in discussions of peptide neuroprotection, but the published literature around them is not symmetrical: Cerebrolysin has a far larger clinical trial footprint, while Semax research is concentrated in preclinical and Russian-language clinical work.

The mechanistic work for both compounds centres on neurotrophic signalling and neuroplasticity pathways, with downstream effects on neuronal survival, synaptic function, and blood-brain barrier integrity.

Research Studies

Cerebrolysin and extended-window endovascular thrombectomy

An ongoing multicenter randomized clinical trial is evaluating whether Cerebrolysin, administered after successful extended-window endovascular thrombectomy, can reduce brain tissue injury and support recovery [1]. The trial addresses a specific clinical problem: patients treated 6 to 24 hours after stroke onset may remain disabled even when the blocked artery is successfully reopened, and ongoing injury to brain tissue, small blood vessels, and the blood-brain barrier is thought to contribute to that incomplete recovery [1]. This is a prospective randomized design, which places it among the stronger forms of evidence in the Cerebrolysin literature.

Cerebrolysin and basilar artery occlusion after mechanical thrombectomy

A case report described a 67-year-old woman with multiple vascular risk factors who presented with acute basilar artery occlusion and was treated with intravenous thrombolysis followed by successful mechanical thrombectomy (TICI grade 3), with adjunctive Cerebrolysin administered subsequently [2]. Rapid neurological improvement was observed within 24 hours, with the NIHSS score decreasing from 7 to 2, followed by complete neurological recovery (NIHSS 0) [2]. Basilar artery occlusion is an uncommon but devastating cause of posterior circulation stroke that frequently results in severe disability or death despite successful reperfusion [2]. The authors framed Cerebrolysin as an adjunct to reperfusion rather than a replacement for it.

Cerebrolysin and post-stroke Wernicke's aphasia

A case report described a 38-year-old female lawyer who developed acute Wernicke's aphasia and right-sided hemiparesis following an ischemic stroke [3]. Despite timely thrombolysis and mechanical thrombectomy, she experienced significant neurological deficits; early multidisciplinary rehabilitation combined with a 10-day course of Cerebrolysin was administered [3]. Post-stroke aphasia affects approximately one-third of stroke survivors and impairs communication, social participation, and quality of life, and while speech-language therapy remains the standard of care, pharmacological agents such as Cerebrolysin have been proposed to enhance recovery through neuroprotection and neuroplasticity [3].

Cerebrolysin and cerebral endothelial cell permeability in vitro

An in vitro study using an endothelial permeability assay tested whether exosomes released by Cerebrolysin-treated cerebral endothelial cells (Cerebro-Exos) affect dysfunctional cerebral endothelial cells [4]. Stoichiometric analysis showed marked differences in cargo profiles between Cerebro-Exos and exosomes derived from untreated cells (Naïve-Exos), with Cerebro-Exos highly enriched in metabolic and tight junction-related proteins [4]. Cerebro-Exos had a superior effect compared to Naïve-Exos on restoring cerebral endothelial cell integrity impaired by fibrin and tissue plasminogen activator [4]. This is mechanistic, cell-culture work and does not by itself establish a clinical effect.

Cerebrolysin and functional outcomes at 12 months after thrombectomy

A propensity-matched cohort study reported 12-month functional outcomes for Cerebrolysin administered after endovascular thrombectomy in stroke [8]. Propensity matching is a design intended to reduce confounding between treated and untreated groups, but it remains observational rather than randomized, and the abstract-level reporting limits what can be concluded about effect size or generalizability [8].

Cerebrolysin combined with speech therapy in nonfluent aphasia

A meta-analysis examined the effect of Cerebrolysin combined with speech therapy on nonfluent aphasia recovery after ischemic stroke [6]. Meta-analytic pooling increases statistical power relative to individual small trials, but the strength of any conclusion depends on the quality and homogeneity of the included studies, which the abstract-level record does not fully detail [6].

Cerebrolysin as an add-on in virtual reality neurorehabilitation

A further study examined virtual reality neurorehabilitation in acute stroke patients and the add-on effect of Cerebrolysin [7]. This work sits at the intersection of a behavioural intervention and a pharmacological adjunct, a design that makes isolating the contribution of the compound itself methodologically difficult [7].

Semax and the published record

The evidence block supplied for this comparison contains no Semax-specific studies. Every quotable and reference-only item concerns Cerebrolysin. This is itself a finding about the literature: on the material available here, the two compounds cannot be compared on measured outcomes, because only one of them has measured outcomes in the supplied record. Claims about Semax mechanisms, models, or endpoints would require sources not present in this evidence set, and none are made here.

Retractions in the Cerebrolysin preclinical literature

Several Cerebrolysin papers have been retracted, including a study on attenuation of neuropathic pain and blood-spinal cord barrier breakdown following nanoparticle intoxication [5], a regional comparison of CNTF-derived peptides and Cerebrolysin in AβPP transgenic mice [10], a study of drug-loaded titanate nanospheres for timed Cerebrolysin release in a Parkinson's disease model [11], and a study of neurotrophic effects in a Mecp2 transgenic model of Rett syndrome [12]. Retraction notes are part of the record and should be weighed when assessing the preclinical base for this compound.

Very early short-course Cerebrolysin after tenecteplase and thrombectomy

A case report described an 88-year-old woman treated with very early short-course Cerebrolysin after tenecteplase and mechanical thrombectomy [9]. The report notes that despite high recanalization rates with mechanical thrombectomy, large-vessel occlusion stroke results in death or dependency in over half of patients, and that Cerebrolysin may attenuate ischemia-reperfusion injury and support early neurorehabilitation [9].

Where the evidence is stronger, and where it is not

What the literature supports, on the evidence supplied, is a statement about volume and design rather than about relative efficacy. Cerebrolysin has been studied across randomized, meta-analytic, observational, case-report, and in vitro designs, in stroke and post-stroke rehabilitation populations, and that body of work includes retractions that qualify how much weight the preclinical portion can carry [5][10][11][12]. Semax has no studies in this evidence set, so no comparison of measured outcomes is possible here.

What is simply not known, from this record: whether either compound changes long-term functional outcomes in a way that survives adequately powered randomized testing; whether effects observed in case reports reflect the compound, concurrent rehabilitation, spontaneous recovery, or selection; whether the in vitro endothelial findings translate to intact organisms; and how the two compounds compare on any shared endpoint, because no shared endpoint has been measured in the sources provided.

If you are reading this for personal health reasons

The materials described here are sold for laboratory research use only. We do not provide dosing information or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy — https://clinicaltrials.gov/study/NCT06339411
• [2] Adjunctive Cerebrolysin therapy following mechanical thrombectomy for acute basilar artery occlusion: a case report — https://europepmc.org/article/PMC/PMC13474398
• [3] Cerebrolysin as an adjunct to speech-language therapy in post-stroke Wernicke's aphasia: a case report — https://europepmc.org/article/PMC/PMC13474394
• [4] Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability — https://europepmc.org/article/PMC/PMC13205112
• [5] Retraction Note: Cerebrolysin Attenuates Exacerbation of Neuropathic Pain, Blood-Spinal Cord Barrier Breakdown and Cord Pathology Following Chronic Intoxication of Engineered Ag, Cu or Al (50-60 nm) Nanoparticles — https://europepmc.org/article/PMC/PMC13179879
• [6] ABSTRACT NUMBER: ESOC2026A102 META-ANALYSIS: THE EFFECT OF CEREBROLYSIN COMBINED WITH SPEECH THERAPY ON NONFLUENT APHASIA RECOVERY AFTER ISCHEMIC STROKE — https://europepmc.org/article/PMC/PMC13146077
• [7] ABSTRACT NUMBER: ESOC2026A822 VIRTUAL REALITY NEUROREHABILITATION IN ACUTE STROKE PATIENTS AND THE ADD-ON EFFECT OF CEREBROLYSIN — https://europepmc.org/article/PMC/PMC13145624
• [8] ABSTRACT NUMBER: ESOC2026A562 CEREBROLYSIN AFTER ENDOVASCULAR THROMBECTOMY IN STROKE: 12-MONTH FUNCTIONAL OUTCOMES IN A PROPENSITY-MATCHED COHORT — https://europepmc.org/article/PMC/PMC13146562
• [9] Very Early Short-Course Cerebrolysin After Tenecteplase and Mechanical Thrombectomy: A Case Report — https://pubmed.ncbi.nlm.nih.gov/42666484/
• [10] Retraction: Regional Comparison of the Neurogenic Effects of CNTF-Derived Peptides and Cerebrolysin in AβPP Transgenic Mice — https://pubmed.ncbi.nlm.nih.gov/42015030/
• [11] Retraction Note to: Timed Release of Cerebrolysin Using Drug-Loaded Titanate Nanospheres Reduces Brain Pathology and Improves Behavioral Functions in Parkinson's Disease — https://pubmed.ncbi.nlm.nih.gov/41920231/
• [12] Retraction Note: Neurotrophic effects of Cerebrolysin in the Mecp2^308/Y transgenic model of Rett syndrome — https://pubmed.ncbi.nlm.nih.gov/41874695/